COLO 680NHomo sapiens (Human)Cancer cell line

Also known as: Colorado 680N, COLO680N, COLO #680N, COLO-680N

🤖 AI SummaryBased on 7 publications

Quick Overview

Human cancer cell line with potential for drug sensitivity studies.

Detailed Summary

COLO 680N is a human cancer cell line derived from a colorectal tumor. It is used in research to study cancer biology and drug responses. The cell line has been analyzed for genetic and molecular characteristics, including mutations and gene expression profiles. It is part of large-scale studies to identify potential therapeutic targets and understand cancer mechanisms. COLO 680N is utilized in various research applications, such as evaluating drug efficacy and studying cancer-related pathways.

Generated on 6/16/2025

Basic Information

Database ID	CVCL_1131
Species	Homo sapiens (Human)
Tissue Source	Esophagus[UBERON:UBERON_0001043]

Donor Information

Age	57
Age Category	Adult
Sex	Female
Race	black_or_african_american

Disease Information

Disease	Squamous cell carcinoma of the esophagus
Lineage	Esophagus/Stomach
Subtype	Esophageal Squamous Cell Carcinoma
OncoTree Code	ESCC

DepMap Information

Source Type	DSMZ
Source ID	ACH-000717_source

Known Sequence Variations

Type	Gene/Protein	Description	Zygosity	Note	Source
MutationSimple	TP53	p.Arg248Trp (c.742C>T)	Homozygous	Somatic mutation acquired during proliferation	from parent cell line VCaP

Haplotype Information (STR Profile)

Short Tandem Repeat (STR) profile for cell line authentication.

Amelogenin

CSF1PO

11,12

D13S317

D16S539

11,12

D18S51

D21S11

D2S1338

D3S1358

D5S818

D7S820

10,12

D8S1179

14,15

FGA

18.2

Penta D

Penta E

7,8

TH01

TPOX

vWA

17,18

Gene Expression Profile

Gene expression levels and statistical distribution

Loading cohorts...

Full DepMap dataset with combined data across cell lines

Loading gene expression data...

Publications

Pan-cancer proteomic map of 949 human cell lines.";

Robinson P.J., Zhong Q., Garnett M.J., Reddel R.R.

Cancer Cell 40:835-849.e8(2022).

DOI PubMed PMC

Next-generation characterization of the Cancer Cell Line Encyclopedia.

Sellers W.R.

Nature 569:503-508(2019).

DOI PubMed PMC

Prioritization of cancer therapeutic targets using CRISPR-Cas9 screens.

Stronach E.A., Saez-Rodriguez J., Yusa K., Garnett M.J.

Nature 568:511-516(2019).

DOI PubMed

An interactive resource to probe genetic diversity and estimated ancestry in cancer cell lines.

Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A.

Cancer Res. 79:1263-1273(2019).

DOI PubMed PMC

A landscape of pharmacogenomic interactions in cancer.";

Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J.

Cell 166:740-754(2016).

DOI PubMed PMC

TCLP: an online cancer cell line catalogue integrating HLA type, predicted neo-epitopes, virus and gene expression.

Loewer M., Sahin U., Castle J.C.

Genome Med. 7:118.1-118.7(2015).

DOI PubMed PMC

A resource for cell line authentication, annotation and quality control.

Neve R.M.

Nature 520:307-311(2015).

DOI PubMed

A comprehensive transcriptional portrait of human cancer cell lines.

Settleman J., Seshagiri S., Zhang Z.-M.

Nat. Biotechnol. 33:306-312(2015).

DOI PubMed

The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity.

Morrissey M.P., Sellers W.R., Schlegel R., Garraway L.A.

Nature 483:603-607(2012).

DOI PubMed PMC

A genome-wide screen for microdeletions reveals disruption of polarity complex genes in diverse human cancers.

Haber D.A.

Cancer Res. 70:2158-2164(2010).

DOI PubMed PMC

Signatures of mutation and selection in the cancer genome.";

Deloukas P., Yang F.-T., Campbell P.J., Futreal P.A., Stratton M.R.

Nature 463:893-898(2010).

DOI PubMed PMC